14 июл. 2023 г. · Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases · Eli Lilly and Company (NYSE: LLY) and Versanis Bio today ...

14 авг. 2023 г. · The acquisition expands Lilly 's portfolio to include Versanis' lead asset, bimagrumab, which is currently being assessed in a Phase 2b study ...

14 июл. 2023 г. · The Indianapolis-based company has signed off on a $1.92 billion deal, which covers an upfront payment and potential milestones, for Boston-based Versanis and ...

14 июл. 2023 г. · Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic ...

17 июл. 2023 г. · Eli Lilly and Company has signed an agreement for the acquisition of clinical-stage biopharmaceutical firm Versanis Bio in a $1.925bn deal.

14 авг. 2023 г. · The acquisition expands Lilly's portfolio to include Versanis' lead asset, bimagrumab, which is currently being assessed in a Phase 2b study ...

14 июл. 2023 г. · Eli Lilly and Co said on Friday it will buy privately held Versanis for potentially up to $1.93 billion to strengthen its position in the ...

14 июл. 2023 г. · The pharmaceutical company will pay up to $1.9 billion to acquire the privately held biotech and its experimental antibody.

20 июл. 2023 г. · Eli Lilly and Company and Versanis Bio have announced a definitive agreement for Lilly to pay up to $1.925 billion in cash to acquire ...

15 авг. 2023 г. · Eli Lilly and Company (Lilly) has announced the completion of several previously announced acquisitions: Versanis Bio (Versanis), Sigilon ...